Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi:10.3322/caac.21332.
   PubMed Web of Science ®Google Scholar
• Martinez-Lostao L, Anel A, Pardo J. How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clin Cancer Res. 2015;21:5047–56. doi:10.1158/1078-0432.CCR-15-0685. PMID:26567364.
   PubMed Web of Science ®Google Scholar
• Balkhi MY, Ma Q, Ahmad S, Junghans RP. T cell exhaustion and Interleukin 2 downregulation. Cytokine. 2015;71:339–47. doi:10.1016/j.cyto.2014.11.024. PMID:25516298.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123–35. doi:10.1056/NEJMoa1504627. PMID:26028407.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627–39. doi:10.1056/NEJMoa1507643. PMID:26412456.
   PubMed Web of Science ®Google Scholar
• Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Yanhuang null, Zhao H, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090. doi:10.1038/srep20090. PMID:26822379.
   PubMed Web of Science ®Google Scholar
• Lim SH, Hong M, Ahn S, Choi Y-L, Kim K-M, Oh D, Ahn YC, Jung S-H, Ahn M-J, Park K, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer Oxf Engl 1990. 2016;52:1–9.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim M-Y, Koh J, Go H, Lee DS, Jeon YK, Chung DH. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. Eur J Cancer Oxf Engl 1990. 2015;51:2698–707..
   PubMed Web of Science ®Google Scholar
• Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:147–53. doi:10.1093/annonc/mdv489.
   PubMed Web of Science ®Google Scholar
• Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, et al. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12:1536–43.
   Google Scholar
• Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P, Lorenzo M, Menéndez S, Salido M, Albanell J, Pijuan L, et al. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. Clin Lung Cancer. 2017;18:682–91. e5. doi:10.1016/j.cllc.2017.04.014. PMID:28549836.
   PubMed Web of Science ®Google Scholar
• Uruga H, Bozkurtlar E, Huynh TG, Muzikansky A, Goto Y, Gomez-Caraballo M, Hata AN, Gainor JF, Mark EJ, Engelman JA, et al. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12:458–66.
   Google Scholar
• Pinato DJ, Shiner RJ, White SDT, Black JRM, Trivedi P, Stebbing J, Sharma R, Mauri FA. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology. 2016;5:e1213934. doi:10.1080/2162402X.2016.1213934. PMID:27757309.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1953–8. doi:10.1093/annonc/mdw289.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11. doi:10.1126/science.aad0095. PMID:26359337.
   PubMed Web of Science ®Google Scholar
• Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017;19:1189–201. doi:10.1016/j.celrep.2017.04.031. PMID:28494868.
   PubMed Web of Science ®Google Scholar
• Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 2017;28:1996–2001. doi:10.1093/annonc/mdx212. PMID:28459943.
   PubMed Web of Science ®Google Scholar
• Iijima Y, Hirotsu Y, Amemiya K, Ooka Y, Mochizuki H, Oyama T, Nakagomi T, Uchida Y, Kobayashi Y, Tsutsui T, et al. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. Eur J Cancer Oxf Engl 1990. 2017;86:349–57.
   PubMed Web of Science ®Google Scholar
• Giroux Leprieur E, Herbretau G, Dumenil C, Julie C, Giraud V, Labrune S, Dumoulin J, Tisserand J, Emile J-F, Blons H, et al. Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. OncoImmunology. 2018. doi:10.1080/2162402X.2018.1424675.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, et al. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015;6:534–8. doi:10.1111/1759-7714.12247. PMID:26273411.
   PubMed Web of Science ®Google Scholar
• Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer Amst Neth. 2017;104:1–6. doi:10.1016/j.lungcan.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang P, Wang J, Xi Q, Zhao X, Ji M, Hu G. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine (Baltimore). 2017;96:e6102. doi:10.1097/MD.0000000000006102. PMID:28207525.
   PubMed Web of Science ®Google Scholar
• Adam J, Rouquette I, Damotte D, Badoual C, Danel C, Damiola F, Penault-Llorca F, Lantuejoul S. Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12 (1s):PL04a.04.
   Google Scholar
• Trapani JA, Sutton VR. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol. 2003;15:533–43. doi:10.1016/S0952-7915(03)00107-9. PMID:14499262.
   PubMed Web of Science ®Google Scholar
• Waterhouse NJ, Sutton VR, Sedelies KA, Ciccone A, Jenkins M, Turner SJ, Bird PI, Trapani JA. Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. J Cell Biol. 2006;173:133–44. doi:10.1083/jcb.200510072. PMID:16606695.
   PubMed Web of Science ®Google Scholar
• Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Froelich CJ, Hack CE. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999;116:366–70. doi:10.1046/j.1365-2249.1999.00881.x. PMID:10337032.
   PubMed Web of Science ®Google Scholar
• Kondo H, Hojo Y, Tsuru R, Nishimura Y, Shimizu H, Takahashi N, Hirose M, Ikemoto T, Ohya K-I, Katsuki T, et al. Elevation of plasma granzyme B levels after acute myocardial infarction. Circ J Off J Jpn Circ Soc. 2009;73:503–7.
   PubMed Web of Science ®Google Scholar
• Skjelland M, Michelsen AE, Krohg-Sørensen K, Tennøe B, Dahl A, Bakke S, Brosstad F, Damås JK, Russell D, Halvorsen B, et al. Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity. Atherosclerosis. 2007;195:e142–146. doi:10.1016/j.atherosclerosis.2007.05.001. PMID:17568588.
   PubMed Web of Science ®Google Scholar
• Naidu S, Garofalo M. microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance. Front Med. 2015;2:77. doi:10.3389/fmed.2015.00077..
   PubMed Web of Science ®Google Scholar
• Zhou S, Dong X, Zhang C, Chen X, Zhu J, Li W, Song X, Xu Z, Zhang W, Yang X, et al. MicroRNAs are implicated in the suppression of CD4+CD25− conventional T cell proliferation by CD4+CD25+ regulatory T cells. Mol Immunol. 2015;63:464–72. doi:10.1016/j.molimm.2014.10.001. PMID:25457879.
   PubMed Web of Science ®Google Scholar
• Wei J, Nduom EK, Kong L-Y, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, et al. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncol. 2016;18:639–48. doi:10.1093/neuonc/nov292. PMID:26658052.
   PubMed Web of Science ®Google Scholar
• Ali MA, Matboli M, Tarek M, Reda M, Kamal KM, Nouh M, Ashry AM, El-Bab AF, Mesalam HA, Shafei AE-S, et al. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy? Immunotherapy. 2017;9:99–108. doi:10.2217/imt-2016-0111. PMID:28000527.
   PubMed Web of Science ®Google Scholar
• Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin M-L, Begum J, Baker A-M, Amgheib A, Saif J, et al. The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget. 2017;8:21609–25. doi:10.18632/oncotarget.15450. PMID:28423491.
   PubMedGoogle Scholar
• Khorrami S, Zavaran Hosseini A, Mowla SJ, Soleimani M, Rakhshani N, Malekzadeh R. MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017;39:1010428317698365. doi:10.1177/1010428317698365.
   Web of Science ®Google Scholar
• Xu C, Zhang Y, Wang Q, Xu Z, Jiang J, Gao Y, Gao M, Kang J, Wu M, Xiong J, et al. Long non-coding RNA GAS5 controls human embryonic stem cell self-renewal by maintaining NODAL signalling. Nat Commun. 2016;7:13287. doi:10.1038/ncomms13287. PMID:27811843.
   PubMed Web of Science ®Google Scholar
• Yee D, Shah KM, Coles MC, Sharp TV, Lagos D. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem. 2017;292:20683–93. doi:10.1074/jbc.M117.809053. PMCID: PMC5733604.
   Web of Science ®Google Scholar
• Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016;108:djv303. doi:10.1093/jnci/djv303. PMID:26577528.
   PubMedGoogle Scholar
• Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 2016;7:45370–84. PMID:27248318.
   PubMedGoogle Scholar
• Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, Zhou H, Li R, Wang K, Wang W, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol. 2014;75:348–53. doi:10.1016/j.humimm.2014.01.006. PMID:24468585.
   PubMed Web of Science ®Google Scholar
• Li Q, Johnston N, Zheng X, Wang H, Zhang X, Gao D, Min W. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget. 2016;7:53735–50. PMID:27447564.
   PubMedGoogle Scholar
• Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, Wei J, Chen X, Weng Y, He T, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27:443–52. doi:10.1016/j.cellsig.2014.12.003. PMID:25499621.
   PubMed Web of Science ®Google Scholar
• Lv Q-L, Du H, Liu Y-L, Huang Y-T, Wang G-H, Zhang X, Chen S-H, Zhou H-H. Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma. Oncol Rep. 2017;38:959–66. doi:10.3892/or.2017.5762. PMID:28656255.
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang Q, Xia N, Yang H, Hu C. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res. 2012;40:1662–9. doi:10.1177/030006051204000505. PMID:23206448.
   PubMed Web of Science ®Google Scholar
• Chen L-J, Li X-Y, Zhao Y-Q, Liu W-J, Wu H-J, Liu J, Mu X-Q, Wu H-B. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance. Pathol Res Pract. 2017;213:882–8. doi:10.1016/j.prp.2017.06.012. PMID:28688608.
   PubMed Web of Science ®Google Scholar
• Zou Q, Yi W, Huang J, Fu F, Chen G, Zhong D. MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells. Exp Ther Med. 2017;14:1198–204. doi:10.3892/etm.2017.4593. PMID:28810579.
   PubMed Web of Science ®Google Scholar
• Dai X, Chiang Y, Wang Z, Song Y, Lu C, Gao P, Xu H. Expression levels of microRNA-375 in colorectal carcinoma. Mol Med Rep. 2012;5:1299–304. PMID:22377847.
   PubMed Web of Science ®Google Scholar
• Xu L, Li M, Wang M, Yan D, Feng G, An G. The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. BMC Cancer. 2014;14:714. doi:10.1186/1471-2407-14-714. PMID:25255814.
   PubMed Web of Science ®Google Scholar
• Alam KJ, Mo J-S, Han S-H, Park W-C, Kim H-S, Yun K-J, Chae S-C. MicroRNA 375 regulates proliferation and migration of colon cancer cells by suppressing the CTGF-EGFR signaling pathway. Int J Cancer. 2017;141:1614–29. doi:10.1002/ijc.30861. PMID:28670764.
   PubMed Web of Science ®Google Scholar
• Xu L, Wen T, Liu Z, Xu F, Yang L, Liu J, Feng G, An G. MicroRNA-375 suppresses human colorectal cancer metastasis by targeting Frizzled 8. Oncotarget. 2016;7:40644–56. PMID:27276676.
   PubMedGoogle Scholar
• Lv H, He Z, Wang H, Du T, Pang Z. Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication. Am J Transl Res. 2016;8:3288–98. PMID:27508050.
   PubMed Web of Science ®Google Scholar
• Hu C, Lv L, Peng J, Liu D, Wang X, Zhou Y, Huo J. MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression. Oncol Lett. 2017;13:4769–75. doi:10.3892/ol.2017.6098. PMID:28599478.
   PubMed Web of Science ®Google Scholar
• Lee SW, Park KC, Kim JG, Moon SJ, Kang SB, Lee DS, Sul HJ, Ji JS, Jeong HY. Dysregulation of MicroRNA-196b-5p and MicroRNA-375 in Gastric Cancer. J Gastric Cancer. 2016;16:221–9. doi:10.5230/jgc.2016.16.4.221. PMID:28053808.
   PubMed Web of Science ®Google Scholar
• Lian S, Park JS, Xia Y, Nguyen TT, Joo YE, Kim KK, Kim HK, Jung YD. MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais. Int J Mol Sci. 2016;17:p. 1633. doi:10.3390/ijms17101633.
   Web of Science ®Google Scholar
• Zhou J, Song S, Cen J, Zhu D, Li D, Zhang Z. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol Res. 2012;20:197–203. doi:10.3727/096504013X13589503482734. PMID:23581226.
   PubMed Web of Science ®Google Scholar
• Song S, Zhou J, He S, Zhu D, Zhang Z, Zhao H, Wang Y, Li D. Expression levels of microRNA-375 in pancreatic cancer. Biomed Rep. 2013;1:393–8. doi:10.3892/br.2013.88. PMID:24648956.
   PubMedGoogle Scholar
• Cui F, Wang S, Lao I, Zhou C, Kong H, Bayaxi N, Li J, Chen Q, Zhu T, Zhu H. miR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes. Oncol Rep. 2016;36:487–93. doi:10.3892/or.2016.4834. PMID:27222350.
   PubMed Web of Science ®Google Scholar
• Yang D, Yan R, Zhang X, Zhu Z, Wang C, Liang C, Zhang X. Deregulation of MicroRNA-375 inhibits cancer proliferation migration and chemosensitivity in pancreatic cancer through the association of HOXB3. Am J Transl Res. 2016;8:1551–9. PMID:27186281.
   PubMed Web of Science ®Google Scholar
• Kong KL, Kwong DLW, Chan TH-M, Law SY-K, Chen L, Li Y, Qin Y-R, Guan X-Y. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33–42. doi:10.1136/gutjnl-2011-300178. PMID:21813472.
   PubMed Web of Science ®Google Scholar
• Liu AM, Poon RTP, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394:623–7. doi:10.1016/j.bbrc.2010.03.036. PMID:20226166.
   PubMed Web of Science ®Google Scholar
• Shao Y, Geng Y, Gu W, Huang J, Ning Z, Pei H. Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis. Dis Markers. 2014;2014:626185. doi:10.1155/2014/626185. PMID:25404787.
   PubMedGoogle Scholar
• Hu Y, Wang L, Gu J, Qu K, Wang Y. Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. Oncotarget. 2017;8:74554–66. PMID:29088807.
   PubMedGoogle Scholar
• Chen X, Li B, Luo R, Cai S, Zhang C, Cao X. Analysis of the function of microRNA-375 in humans using bioinformatics. Biomed Rep. 2017;6:561–6. doi:10.3892/br.2017.889. PMID:28515914.
   PubMed Web of Science ®Google Scholar
• Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2017;36:24–34. doi:10.1038/onc.2016.185. PMID:27270433.
   PubMed Web of Science ®Google Scholar
• Spranger S, Gajewski TF. A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. J Immunother Cancer. 2015;3:43. doi:10.1186/s40425-015-0089-6. PMID:26380088.
   PubMed Web of Science ®Google Scholar
• Ramos RN, Piaggio E, Romano E. Mechanisms of Resistance to Immune Checkpoint Antibodies. Handb Exp Pharmacol. 2017; doi:10.1007/164_2017_11. PMID:28315073. [Epub ahead of print]
   PubMedGoogle Scholar
• Moroishi T, Hayashi T, Pan W-W, Fujita Y, Holt MV, Qin J, Carson DA, Guan K-L. The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell. 2016;167:1525–39. e17.
   PubMed Web of Science ®Google Scholar
• Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, Szustakowski JD. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PloS One. 2017;12:e0179726. doi:10.1371/journal.pone.0179726. PMID:28749946.
   PubMed Web of Science ®Google Scholar
• Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, et al. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:6054–61. doi:10.1158/1078-0432.CCR-16-1688..
   PubMed Web of Science ®Google Scholar
• Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol OncolJ Hematol Oncol. 2017;10:101. doi:10.1186/s13045-017-0471-6..
   PubMed Web of Science ®Google Scholar
• Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, et al. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. Eur J Cancer Oxf Engl 1990. 2017;78:70–81.
   PubMed Web of Science ®Google Scholar
• Wei R, Yang Q, Han B, Li Y, Yao K, Yang X, Chen Z, Yang S, Zhou J, Li M, et al. microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways. Oncotarget. 2017;8:16633–41. PMID:28186962.
   PubMedGoogle Scholar
• Wang J, Huang H, Wang C, Liu X, Hu F, Liu M. MicroRNA-375 sensitizes tumour necrosis factor-alpha (TNF-α)-induced apoptosis in head and neck squamous cell carcinoma in vitro. Int J Oral Maxillofac Surg. 2013;42:949–55. doi:10.1016/j.ijom.2013.04.016. PMID:23726271.
   PubMed Web of Science ®Google Scholar
• Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11:R25. doi:10.1186/gb-2010-11-3-r25. PMID:20196867.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40. doi:10.1093/bioinformatics/btp616. PMID:19910308.
   PubMed Web of Science ®Google Scholar
• McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012;40:4288–97. doi:10.1093/nar/gks042. PMID:22287627.
   PubMed Web of Science ®Google Scholar
• Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, Mahaffey S, Rossi S, Calin GA, Bemis L, et al. The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42:e133−e133. doi:10.1093/nar/gku631. PMID:25063298.
   PubMed Web of Science ®Google Scholar